Primary aldosteronism: New screening recommendations and the role of aldosterone-to-renin ratio testing
By Nathalie Dekeersmaeker, Fujirebio
Primary aldosteronism (PA) is a common cause of hypertension, yet it remains markedly underdiagnosed and undertreated. With the publication of the 2025 Endocrine Society Clinical Practice Guideline, the approach to identifying PA is changing. Screening is no longer focused only on selected high-risk patients: the new guideline suggests screening all individuals with hypertension. At the centre of this approach is the measurement of aldosterone and renin and determination of the aldosterone-to-renin ratio (ARR). 1
Understanding PA
PA is characterised by aldosterone production that is at least partially autonomous from its normal regulator, the renin-angiotensin system. This results in an inappropriate relationship between aldosterone and renin, with renin typically suppressed.
Excess aldosterone promotes renal sodium retention and volume expansion, contributing to elevated blood pressure. Importantly, PA is associated with greater cardiovascular risk than primary hypertension, making its identification clinically relevant.
Despite effective diagnostic and treatment options, PA remains underdiagnosed and undertreated.
New guidelines broaden the scope of screening
The 2025 Endocrine Society Clinical Practice Guideline marks an important change in the approach to PA case detection.
Where previous recommendations focused screening primarily on patients with characteristics associated with a higher probability of PA, the updated guideline suggests screening all individuals with hypertension for PA.
The recommendation is conditional and its implementation may depend on factors such as healthcare resources, local expertise and healthcare system capacity. Nevertheless, the change reflects increasing recognition of PA as an important and potentially treatable cause of hypertension.
As PA screening expands to a broader population of people with hypertension, access to reliable aldosterone and renin testing becomes increasingly relevant.
ARR: bringing aldosterone and renin together
Screening for PA involves measuring both aldosterone and renin. A characteristic feature of PA is:
-
inappropriately high aldosterone production,
-
suppressed renin levels.
This relationship forms the basis of the aldosterone-to-renin ratio (ARR).
From targeted testing towards routine implementation
Expanding PA screening beyond the traditional high-risk populations has implications, not only for clinicians, but also for laboratories.
If more people with hypertension are evaluated for PA, aldosterone and renin testing may increasingly need to move from specialised endocrine testing towards a more routine diagnostic workflow.
This places additional emphasis on:
-
reliable measurement of both aldosterone and renin;
-
standardised laboratory workflows;
-
efficient handling of increasing test volumes;
-
appropriate, method-specific interpretation of the ARR.
Automated solutions can help laboratories integrate these measurements into routine workflows while maintaining consistency between aldosterone and renin testing.
Supporting PA screening on the LUMIPULSE® G System
Fujirebio Inc. offers Lumipulse® G Aldosterone and Lumipulse G Renin CE-marked Assays for automated measurement on the LUMIPULSE G System.
Together, the assays allow laboratories to measure aldosterone and active renin on a single automated platform, providing the two complementary results required for calculation of the ARR.
Both assays use automated specific two-step chemiluminescent enzyme immunoassay (CLEIA) technology. Lumipulse G Aldosterone can be used with serum and plasma, as well as urine with the dedicated pre-treatment procedure, while Lumipulse G Renin measures active renin in serum and plasma.
The assays are designed to support routine laboratory implementation, with mono-test cartridges, liquid calibrators and 30-day calibration stability. Sample requirements are 40 µL for aldosterone and 50 µL for renin.
(source: IFUs)
Get to the heart of hypertension
The updated recommendations represent an important shift in how PA is approached.
For clinicians, the updated screening recommendation highlights the importance of considering PA as a possible underlying cause of hypertension.
For laboratories, it creates a growing need for accessible, standardised and scalable testing of aldosterone and renin.
As screening expands from selected high-risk patients towards broader screening, ARR testing can help get to the heart of hypertension by identifying PA as a possible underlying cause.
Aldosterone + Renin = ARR
Helping to identify PA as a possible underlying cause of hypertension
References:
-
Adler GK, et al. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2025 Aug 7;110(9):2453-2495. doi: 10.1210/clinem/dgaf284. Erratum in: J Clin Endocrinol Metab. 2025 Oct 16;110(11):e3933-e3934. doi: 10.1210/clinem/dgaf472.